相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
Don Husereau et al.
PHARMACOECONOMICS (2022)
Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
Velia Cassano et al.
FRONTIERS IN PHARMACOLOGY (2022)
Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis
Kanila Perera et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Cost-effectiveness analyses of sacubitril-valsartan for heart failure
Xiao-qi Liu et al.
HEART FAILURE REVIEWS (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mortality and Readmission Rates After Heart Failure: A Systematic Review and Meta-Analysis
Tian Lan et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2021)
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
Domingo Pascual-Figal et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
Rungroj Krittayaphong et al.
CLINICAL DRUG INVESTIGATION (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective
Ken Lee Chin et al.
HEART LUNG AND CIRCULATION (2020)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
Yue Wu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study
Mona Alshahawey et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Readmissions in Heart Failure: It's More Than Just the Medicine
Yogesh N. V. Reddy et al.
MAYO CLINIC PROCEEDINGS (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
Rungroj Krittayaphong et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2018)
Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States
Patrick M. Zueger et al.
PHARMACOTHERAPY (2018)
Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry
Yuhui Zhang et al.
JOURNAL OF CARDIAC FAILURE (2017)
Effect of Omega-3 Fatty Acids on Serum Lipid Profile and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized Placebo-Controlled Study
Areej Mohamed Ateya et al.
JOURNAL OF RENAL NUTRITION (2017)
Understanding the economic burden of heart failure in China: impact on disease management and resource utilization
Jun Huang et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study
Mona Alshahawey et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Geographic variations in the PARADIGM-HF heart failure trial
Soren Lund Kristensen et al.
EUROPEAN HEART JOURNAL (2016)
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
Akshay S. Desai et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Thomas A. Gaziano et al.
JAMA CARDIOLOGY (2016)
The war against heart failure: the Lancet lecture
Eugene Braunwald
LANCET (2015)
The vulnerable phase after hospitalization for heart failure
Stephen J. Greene et al.
NATURE REVIEWS CARDIOLOGY (2015)
Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy
Thomas G. von Lueder et al.
CIRCULATION-HEART FAILURE (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
The annual global economic burden of heart failure
Christopher Cook et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Sarah Mangiafico et al.
EUROPEAN HEART JOURNAL (2013)
分享论文
